Denali Therapeutics (DNLI) Receivables (2018 - 2026)

Denali Therapeutics (DNLI) has 9 years of Receivables data on file, last reported at $1.6 million in Q1 2026.

• Receivables for Q1 2026 came in at $1.6 million, down 5.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (down 5.88% YoY), and the FY2025 annual result was $1.6 million, down 26.3% from the prior year.
• Receivables steadied at $1.6 million in Q1 2026 per DNLI's latest filing, from $1.6 million in the prior quarter.
• Over five years, Receivables peaked at $3.4 million in Q2 2023 and troughed at $357000.0 in Q2 2022.
• A 5-year average of $1.9 million and a median of $1.8 million in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2023: Receivables plunged 97.85% in 2022, then jumped 852.38% in 2023.
• A 5-year view of Receivables shows it stood at $357000.0 in 2022, then soared by 656.3% to $2.7 million in 2023, then fell by 19.59% to $2.2 million in 2024, then dropped by 26.3% to $1.6 million in 2025, then changed by 0.0% to $1.6 million in 2026.
• Business Quant data shows DNLI's Receivables at $1.6 million in Q1 2026, $1.6 million in Q4 2025, and $1.9 million in Q3 2025.